Accepting Shenogen chairman, Dr. Meng’s invitation, Dr. Hong (George) Guo, formerly Novartis’ Global Monitoring Operation (GMO) Country Head for China, has joined Beijing Shenogen Pharma Group as Chief Medical Officer (CMO) and Vice President for Clinical Development.  Dr. Guo has more than 20 years of experience in clinical development, and has led many clinical research programs at several multinational pharmaceutical companies.  Prior to joining Shenogen, Dr. Guo was responsible for all of Novartis’ late stage oncology clinical programs and managed a 60+ oncology clinical development team.  He is very strong in the execution of clinical development and has insights in clinical trial practices.  Dr. Guo is well connected with oncology clinical trial PIs in many large hospitals in China, and led many successful Phase III oncology trial programs.  Having him on board will provide assurance in successful clinical trials for the icaritin and the oncolytic virus programs.